About OncoAssure

OncoAssure is a medical diagnostics company that identifies, develops, and commercialises clinically important biomarkers to significantly improve cancer management and treatment. We aim to help clinicians provide the right treatment to the right patient at the right time.

OncoAssure has its origins in OncoMark Ltd. where the OncoMasTR assay for early-stage breast cancer was developed and CE marked in 2018. OncoMark was acquired by Cepheid Inc in 2021 with OncoMasTR being commercialised under the name Xpert Insight Breast Cancer on the GeneXpert system.

 
 
Product-Development.jpg
 

Product Development

OncoAssure’s lead product is a post-biopsy test for prostate cancer that measures the expression of genes that are key drivers of cancer progression.

This test will accurately identify patients with less aggressive disease who can confidently avoid aggressive therapies. The test utilises the OncoAssure process to identify key drivers of cancer progression. This process can be applied in other cancers where significant unmet needs also exist.

 
About-Us-Background-1.jpg
 

The OncoAssure Team

The OncoAssure team have the key skills, expertise, and a proven track record in identifying, developing, and commercialising cancer biomarkers.

The team previously developed the OncoMasTR breast cancer prognostic test at OncoMark Limited which was acquired by Cepheid Inc. in March 2021.

The test, which was validated in three independent studies with over 2,000 patients and achieved Level I evidence, will now be commercialised on Cepheid’s world-leading GeneXpert Platform under the name Xpert Insight Breast Cancer.